| 通報號: G/TBT/N/CAN/469 |
ICS號: 11.120
|
發布日期: 2015-10-08
|
截至日期: 2015-10-08
|
通報成員: 加拿大
|
目標和理由: 保護人類安全和健康
|
內容概述: 本評議通知的目的是提供機會，評議通過修訂人用處方藥清單（PDL）將布洛芬的某些用途轉變為人用非處方藥的提案。
|
正文:
| 世界貿易組織 |
G/TBT/N/CAN/469
2015-10-08
15-5235
|
| |
| 技術性貿易壁壘 |
原文：英語/法語
|
通 報
以下通報根據TBT協定第10.6條分發
| 1. |
通報成員: 加拿大
如可能，列出涉及的地方政府名稱 ( 3.2條和7.2 條)：
|
| 2. |
負責機構:衛生部
|
| 3. |
通報依據條款:
[ ] 2.9.2
[ ] 2.10.1
[ ] 5.6.2
[ ] 5.7.1
通報依據的條款其他：
|
| 4. |
覆蓋的產品： 人用處方藥藥物成分。其它。 ICS: 11.120 HS: 3004.90、300490
HS編碼:300490 ICS編碼:11.120
|
| 5. |
通報標題： 評議通知－處方藥清單（PDL）：布洛芬
語言：英語和法語 頁數：2 鏈接網址：
|
| 6. |
內容簡述： 本評議通知的目的是提供機會，評議通過修訂人用處方藥清單（PDL）將布洛芬的某些用途轉變為人用非處方藥的提案。
|
| 7. |
目標與理由:保護人類健康安全
|
| 8. |
|
| 9. |
擬批準日期:-
擬生效日期:-
[ ] 通報日后6個月，及/或(年月日)： 2015/12/16 [ ] 貿易促進措施
|
| 10. |
意見反饋截止日期：
[ ] 通報發布日起60天，及/或(年/月/日):
|
| 11. |
文本可從以下機構得到:
[ ] 國家通報機構
[ ] 國家咨詢點，或其他機構的聯系地址、傳真及電子郵件地址(如能提供):
|
|
正文(英):
NOTIFICATION
The following notification is being circulated in accordance with Article 10.6
|
1.
|
Notifying Member: Canada
If applicable, name of local government involved (Article 3.2 and 7.2):
|
|
2.
|
Agency responsible: Department of Health
Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:
Canada's Notification Authority and Enquiry Point
Foreign Affairs, Trade and Development Canada
Technical Barriers and Regulations Division (TIB)
111 Sussex Drive
Ottawa, ON K1A 0G2
Canada
Telephone: (343) 203-4273
Fax: (613) 943-0346
Email: enquirypoint@international.gc.ca
|
|
3.
|
Notified under Article 2.9.2 [X], 2.10.1 [ ], 5.6.2 [ ], 5.7.1 [ ], other:
|
|
4.
|
Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable): Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90). – Other (HS: 300490)
|
|
5.
|
Title, number of pages and language(s) of the notified document: Notice of Consultation – Prescription Drug List (PDL): Ibuprofen (2 pages, in English and French)
|
|
6.
|
Description of content: The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to switch certain uses of Ibuprofen to non-prescription status for human use by modifying the Human Prescription Drug List (PDL).
|
|
7.
|
Objective and rationale, including the nature of urgent problems where applicable: Protection of human health or safety
|
|
8.
|
Relevant documents: Health Canada website: http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/lead_pdl_ldo_consult_ibuprofen-eng.php, posted : 2 October 2015 (available in English and French)
|
|
9.
|
Proposed date of adoption: –
Proposed date of entry into force: –
|
|
10.
|
Final date for comments: 16 December 2015
|
|
11.
|
Texts available from: National enquiry point [X] or address, telephone and fax numbers and email and website addresses, if available, of other body:
The electronic version of the notice can be downloaded at:
http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/lead_pdl_ldo_consult_ibuprofen-eng.php
http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/lead_pdl_ldo_consult_ibuprofen-fra.php
|
|
| |
|
| |
|
|
|
本網維權及免責聲明：
①凡本網所有原始/編譯文章及圖片、圖表的版權均屬江蘇省技術性貿易措施信息平臺（www.tbtguide.com)所有，如要轉載，需注明"信息來源：江蘇省技術性貿易措施信息平臺"或"信息來源：tbtguide"。違反上述規定者，本網將保留追究其侵權責任的權利。
②凡本網注明"信息來源：XXX（非tbtguide）"的作品，均轉載自其他媒體，轉載目的在于傳遞更多的信息，并不代表本網贊同其觀點和對其真實性負責。
聯系E-mail：js_wto@163.com |
